x

CRISPR/Cas9 mediated gene modification combined with human iPSC technology provides a powerful tool for generating disease-specific models for drug discovery researchers.

CRISPR-edited cell products

The availability and predictability of human induced pluripotent stem cell (hiPSC) technologies provides new opportunities to inform decision making in drug discovery, and is thereby set to ease translation into the clinic. Now with the assistance of targeted CRISPR/Cas9 gene editing, it is possible to rapidly create cell lines containing disease-associated mutations to uncover the effect on function and phenotype.

We now provide a comprehensive gene-editing and hiPSC differentiation / manufacturing service through a partnership with Horizon Discovery, which delivers predictive and translational in vitro disease models for efficacy screening at any throughput.

Benefits

Freedom to operate - simplified licencing structure, IP protection and path to scale
Isogenic control cells - unedited control available to remove challenge of background-related variability
Efficiency - fully integrated service including hiPSC gene editing, differentiation and manufacturing
Expertise - proven leaders in CRISPR gene editing and stem cell technologies

hiPSC
CRISPR gene editing
Differentiation

hiPSC

At Ncardia we employ state-of-the-art systems for the culture of high-quality hiPSC-derived cell lines. The combination of these systems with our proprietary differentiation protocols allows us to offer a fast and robust industrial-scale manufacturing of the hiPSC-derived cells of interest. Contact us to discuss your cells of interest.

CRISPR/Cas9 gene editing

Through a partnership with Horizon Discovery, CRISPR/Cas9 is used to engineer mutations into induced pluripotent stem cell lines, Cor.4U® or Pluricytes®. A range of custom modifications are available, including knockin, knockout and point mutations. Estimated timelines for generation of the edited clones is 4-6 months.

 

Differentiation

Differentiated terminal cell types are produced from Cor.4U® or Pluricyte® iPS cell lines. The cells are confirmed to be mycoplasma free, sterile, and basic characterization such as impedance and Troponin T measurement are performed. The estimated timeline for this component is 6-9 weeks, depending on the chosen iPSCs.

Additional options

Our dedicated service team is always available for consultation. For custom phenotype investigation, we offer the possibility to secure research & development resources from Ncardia for selected projects. Additionally, the cell lines produced through the service are compatible with many Ncardia standard services and custom services can be developed upon request.

 

More information

§